Logo
Aessoa Global with Lidocaine Monophasic Dermal Filler 1 x 1 ml

Aessoa Global with Lidocaine Monophasic Dermal Filler 1 x 1 ml

Aessoa

Dermal Filler
  • CE Marked hyaluronic acid dermal filler (medical device).
  • MHRA compliant for supply within the UK via registered pharmacies and medical distributors.
  • Manufactured under Good Manufacturing Practice (GMP).
  • Manufactured under ISO 13485 Compliant quality management system (medical devices).
Hyaluronic Acid Monophasic Dermal Filler with Lidocaine

Description

Aessoa Global with Lidocaine is a CE-marked, monophasic, cross-linked hyaluronic acid dermal filler developed by Oreon Life Science for the correction of fine to moderate facial wrinkles, lip contouring, and subtle volume restoration. Formulated with 24 mg/ml non-animal-derived hyaluronic acid and 3 mg/ml lidocaine, it combines effective wrinkle correction and facial contour enhancement with improved patient comfort during treatment. The smooth, homogeneous gel is designed for injection into the mid to deep dermis, delivering natural-looking, long-lasting results while improving skin hydration, texture, and elasticity. As the softest filler in the Aessoa range, it is particularly suited for the lips, perioral and periorbital lines, and other delicate facial areas where refined, subtle outcomes are desired.

Bnefits

  • Treats fine to moderate facial wrinkles and folds (e.g. periorbital, perioral, nasolabial, marionette lines).
  • Enhances and defines lip contours and can be used for gentle lip volumisation.
  • Monophasic cross-linked hyaluronic acid gel for smooth, homogeneous injection and reduced risk of migration.
  • Contains 3 mg/ml lidocaine to increase patient comfort and reduce injection pain.
  • Improves skin hydration, texture, and elasticity through high-concentration hyaluronic acid.
  • Provides natural-looking, subtle volume and contouring with harmonious aesthetic results.
  • Long-lasting clinical effect typically up to 12–18 months depending on area, technique, and patient factors.
  • CE-marked hyaluronic acid dermal filler manufactured under GMP and ISO 13485 quality systems.
  • Suitable for advanced techniques such as lip tenting and precise contour definition in delicate areas.

Indications

  • Correction of fine to moderate facial wrinkles and folds.
  • Treatment of periorbital lines (e.g. crow’s feet).
  • Treatment of perioral lines and early perioral aging signs.
  • Softening of nasolabial folds (mild to moderate).
  • Softening of marionette lines (mild to moderate).
  • Lip contour definition and subtle lip volumisation.
  • Temporal area soft tissue contouring when an appropriate technique is used.
  • General facial contour refinement and rejuvenation in superficial to mid-dermal planes.
  • Improvement of skin hydration and texture in treated areas.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (non-animal origin, monophasic gel).
  • Lidocaine hydrochloride 3 mg/ml (0.3%) as a local anaesthetic.
  • Physiological buffer solution and excipients (q.s.) as per manufacturer’s IFU.

Formulation

  • Injectable, sterile, pyrogen-free, monophasic cross-linked hyaluronic acid gel with lidocaine for intradermal use.
  • Non-animal-derived hyaluronic acid, highly purified with very low BDDE residuals and low endotoxin levels (per Aessoa range specifications).

Packaging

  • Box containing 1 pre-filled 1.0 ml glass syringe of Aessoa Global with Lidocaine.
  • Syringe fitted with Luer-lock connection for compatibility with standard needles and cannulas.
  • Some distributors include 2 x 30G needles per box; others supply the syringe only (no needles included).
  • Individual blister packaging and outer carton labelled with batch number and expiry date.
  • Supplied as a CE-marked medical device for professional use only.

Usage

  • For professional use only; injections must be performed by appropriately trained and licensed healthcare professionals experienced in facial anatomy and dermal filler techniques.
  • Before treatment, obtain a full medical history, assess indications and contraindications, and obtain informed consent according to local regulations.
  • Cleanse and disinfect the treatment area with an appropriate antiseptic solution prior to injection.
  • Recommended injection plane: mid dermis to mid-deep dermis, depending on indication and area treated.
  • Commonly used with a 30G needle or an appropriate microcannula, following the manufacturer’s and distributor’s recommendations.
  • Inject slowly using low, even pressure, with aspiration and adherence to safe injection practices to minimise intravascular injection risk.
  • Shape and gently massage the treated area after injection if required to ensure even product distribution and smooth contours.
  • Avoid overcorrection; take into account expected post-treatment swelling when planning final volume.
  • Advise patients to avoid makeup on the treated area for several hours post-procedure and to follow routine filler aftercare guidance (e.g. avoiding extreme heat/cold, strenuous exercise, and alcohol for 24 hours, and avoiding facial treatments or lasers for a period specified by the practitioner).
  • A touch-up session, if needed, is typically considered after 2–4 weeks, but many patients may not require additional product within this timeframe.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid.
  • Known hypersensitivity or allergy to lidocaine or other amide-type local anaesthetics (for this lidocaine-containing presentation).
  • History of severe allergy or anaphylactic reactions to filler components or similar injectables.
  • Active skin infections, inflammatory skin conditions, or lesions (e.g. acne, herpes, dermatitis) in or near the treatment area.
  • Patients with current or recent systemic infections or uncontrolled systemic disease where injections pose additional risk, according to clinician judgment.
  • Patients with known bleeding disorders or those on significant anticoagulant or antiplatelet therapy where the risk of bleeding or bruising is unacceptable, unless assessed and managed by the prescribing clinician.
  • Pregnant or breastfeeding patients (use is generally not recommended due to lack of safety data).
  • Patients under 18 or under the minimum age permitted by local regulations for aesthetic injectable treatments.
  • Previous hypersensitivity to other hyaluronic acid dermal fillers in the Aessoa range or similar products.
  • Injection into areas with permanent implants, active scars, or compromised tissue viability, unless specifically assessed and deemed appropriate by the treating clinician.
  • Intravascular injection is strictly contraindicated; do not inject into blood vessels.

Adverse Effects

  • Common, usually transient effects at injection site: redness, swelling, tenderness, pain, itching, induration, and mild bruising.
  • Short-term oedema in the treated area, particularly in the lips and periorbital region.
  • Small lumps or nodules at or near the injection site, generally resolving with massage or conservative management.
  • Temporary asymmetry or irregularity related to injection technique or post-treatment swelling.
  • Rare but serious complications typical of hyaluronic acid fillers: vascular occlusion, tissue ischaemia, and potential tissue necrosis if product is inadvertently injected intravascularly or in high-risk zones.
  • Rare inflammatory or hypersensitivity reactions, including prolonged swelling, induration, or delayed inflammatory nodules.
  • Very rare risk of visual disturbance or blindness in the event of retrograde intravascular injection in high-risk anatomical areas, as with other dermal fillers.
  • Any unexpected, severe, or persistent adverse events should be managed according to local clinical protocols and may require hyaluronidase, medical evaluation, or urgent referral.

Storage Conditions

  • Store in a clean, dry place at 2–25°C (36–77°F).
  • Protect from direct sunlight and excessive heat.
  • Do not freeze the product.
  • Keep in the original blister and outer carton until use to maintain sterility and protect from light.
  • Do not use if the packaging or blister is damaged, if the sterility barrier is compromised, or if the expiry date has passed.
  • Keep out of the reach of children and unauthorised persons.

Duration

Typical clinical effect lasts approximately 12\u201318 months, with variability based on injection area, technique, patient metabolism, lifestyle, and skin characteristics.

Onset

Immediate visible improvement after injection, with final results becoming more apparent over several days as initial swelling and minor bruising resolve.

Browse more Dermal Filler

Top Treatments

Top Cities in the UK